Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 2/20 | 0.36 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3681785 | 0.87 | EPHX1 (0.44) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL11655160 | 0.87 | SIGMAR1 (0.52) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL6731887 | 0.85 | EPHX1 (0.43) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL6898174 | 0.85 | EPHX1 (0.43) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL7729378 | 0.85 | EPHX1 (0.43) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL13912981 | 0.83 | SIGMAR1 (0.42) | SIGMAR1CYP1A2EPHX1HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL6890147 | 0.83 | EPHX1 (0.40) | SIGMAR1CYP1A2EPHX1HDAC3HDAC1 | |
| Hydrochloric Acid SCHEMBL4312730 | 0.82 | SIGMAR1 (0.41) | SIGMAR1CYP1A2EPHX1HDAC3HDAC4 | |
| SCHEMBL23131807 | 0.81 | SIGMAR1 (0.59) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL18823178 | 0.81 | SIGMAR1 (0.59) | SIGMAR1CYP1A2KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183232-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11548887-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210024515-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-01-28 | — | — | US | disclosed |
| US-10745394-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190308966-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-10 | — | — | US | disclosed |
| US-10377751-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190119267-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-04-25 | — | — | US | disclosed |
| US-10081626-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-09-25 | — | — | US | disclosed |
| US-20170349578-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-07 | — | — | US | disclosed |
| US-9663509-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-30 | — | — | US | disclosed |
| US-20140288112-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-8664242-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130158060-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8263618-B2 | 8-azabicyclo[3.2.1]octane compounds as MU opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2001876-B1 | 8-AZABICYCLOÝ3.2.1¨OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100035921-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7622508-B2 | 3-Endo-(8-{2-[cyclohexylmethyl-(2-hydroxyacetyl)-amino]-ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-benzamide; for treating condition associated with mu opioid receptor activity, e.g. a disorder of reduced motility of gastrointestinal tract such as opioid-induced bowel dysfunction and post-operative ileus | THERAVANCE, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-2001876-A2 | 8-AZABICYCLOÝ3.2.1¨OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070219278-A1 | 3-Endo-(8-{2-[cyclohexylmethyl-(2-hydroxyacetyl)-amino]-ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-benzamide; for treating condition associated with mu opioid receptor activity, e.g. a disorder of reduced motility of gastrointestinal tract such as opioid-induced bowel dysfunction and post-operative ileus | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-09-20 | — | — | US | disclosed |
| WO-2007103187-A2 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349578-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | SIGMAR1 6/4885CYP1A2 435/4885KDM1A 650/4885 |
| US-20190308966-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | SIGMAR1 6/4885CYP1A2 435/4885KDM1A 650/4885 |
| US-20210024515-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | SIGMAR1 6/4885CYP1A2 435/4885KDM1A 650/4885 |
| US-10377751-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | SIGMAR1 6/4885CYP1A2 435/4885KDM1A 650/4885 |
| US-20190119267-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | SIGMAR1 6/4885CYP1A2 435/4885KDM1A 650/4885 |
| US-20130158060-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | SIGMAR1 6/4885CYP1A2 435/4885KDM1A 650/4885 |
| US-10745394-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | SIGMAR1 6/4885CYP1A2 435/4885KDM1A 650/4885 |
| US-20230183232-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | SIGMAR1 6/4885CYP1A2 435/4885KDM1A 650/4885 |
| US-10081626-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | SIGMAR1 6/4885CYP1A2 435/4885KDM1A 650/4885 |
| US-20100035921-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | SIGMAR1 6/4885CYP1A2 435/4885KDM1A 650/4885 |
| US-11548887-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | SIGMAR1 6/4885CYP1A2 435/4885KDM1A 650/4885 |
| US-20070219278-A1 | 3-Endo-(8-{2-[cyclohexylmethyl-(2-hydroxyacetyl)-amino]-ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-benzamide; for treating condition associated with mu opioid receptor activity, e.g. a disorder of reduced motility of gastrointestinal tract such as opioid-induced bowel dysfunction and post-operative ileus | OPRM1, OPRD1, OGFR | SIGMAR1 6/4885CYP1A2 283/4885KDM1A 302/4885 |
| US-20140288112-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | SIGMAR1 6/4885CYP1A2 435/4885KDM1A 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.